Rory McIlroy, Daniel Ricciardo, Connor McDavid, Klay Thompson, Jayson Tatum and More Join Naomi Osaka, Erling Haaland and Virat Kohli as Hyperice Athlete-Investors to Fuel Global Growth
8.11.2021 14:00:00 EET | Business Wire | Press release
Hyperice, a global high-performance wellness brand specializing in percussion, dynamic air compression, vibration, thermal technology, mind technology, and contrast therapy, today announced new investments from superstars across the sports world including professional golfer Rory McIlroy, Formula One (F1) driver Daniel Ricciardo, NHL player Connor McDavid, NBA player Klay Thompson and NBA player Jayson Tatum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211108005407/en/
Rory McIlroy Joins Join Naomi Osaka, Erling Haaland and Virat Kohli as Hyperice Athlete-Investor to Fuel Global Growth (Photo: Business Wire)
The new investors join an elite list of global athlete-investors such as 4-time tennis Grand Slam champion Naomi Osaka, football superstar Erling Haaland and Indian cricketer Virat Kohli as strategic investors, and quickly follows the company’s entry to mental wellness and evolution into a holistic high-performance wellness brand.
“I am a golfer first and foremost but I am also focused on the long game, which is why I chose to invest in Hyperice,” said professional golfer Rory McIlroy. “Hyperice is an important part of how I practice, play and recover. The company is doing incredible things to redefine and push holistic wellness, so it is an exciting and logical partnership for me and investment partners in Symphony Ventures.”
Other new athlete-investors include 2x NBA All-Star Jayson Tatum, 2x PGA TOUR Champion Tony Finau, 3x NBA Champion Klay Thompson, NBA Champion Khris Middleton, 6x MLB All-Star Nolan Arenado, MLB All-Star Matt Chapman, 4x MLB All-Star Justin Upton, World Series Champion Dexter Fowler, The Masters Champion Sergio Garcia, Professional BMX Athlete Nigel Sylvester, Master Trainer and Performance Specialist Joe Holder, top gaming personality Nicholas Kolcheff, known as NICKMERCS, and more.
These athletes join Hyperice’s current roster of existing high-performing athlete-investors such as Naomi Osaka, Seth Curry, Anthony Davis, Rickie Fowler, DeAndre Jordan, Jarvis Landry, Patrick Mahomes, Christian McCaffrey, Ja Morant, Chris Paul, Ben Simmons, Kelly Slater, Fernando Tatís Jr, J.J. Watt, Russell Westbrook and Trae Young.
“Hyperice’s full suite of products have made a big difference in my recovery and my entire approach to wellness,” said Formula One (F1) driver Daniel Ricciardo. “As Hyperice continues to expand, it felt like the right time to officially put my support into a company that I believe in.”
Now with a global footprint in more than 60 countries, Hyperice is experiencing dramatic global growth driven by an extensive athlete-investors roster, as well as global partnerships in China with the NBA and Leagues of Legends Pro League, the New Zealand national rugby team All Blacks, South Africa national rugby team Springboks, the Mexican Football Federation, and the Tottenham Hotspur Football Club in London.
Reigning National Hockey League (NHL) Most Valuable Player Connor McDavid added: “Hyperice products are a game changer when it comes to supporting both my physical and mental health. Hyperice is not only a brand I personally rely on, but it offers products that benefit all people, no matter what level of athlete they are.”
“This new group of strategic investors will help to fuel Hyperice’s global expansion,” said Jim Huether, Hyperice CEO. “Our international footprint continues to grow with products in more than 60 countries. Partnering with high-performing global athletes like Daniel Ricciardo, Rory McIlroy, Connor McDavid, in addition to the stacked roster we already have, helps continue to separate Hyperice as we continue bringing our innovative suite of products to a broader audience.”
Global Growth and Holistic High-Performance Wellness Brand Evolution
Hyperice recently announced a new stage of global growth as the company evolves into a holistic high-performance wellness brand. The multi-prong transformation, led by Hyperice’s recent acquisition of mental wellness company Core, its third acquisition in the last 18 months, is accompanied by a new brand identity and global brand campaign, and anchored by a suite of new products and industry-first technologies.
Among the new technology advancements include the world's first portable contrast therapy device, Hyperice X, and new generations of Hyperice’s wildly popular Hypervolt and Vyper lines, including the Hypervolt 2, Hypervolt 2 Pro, Vyper 3 and Vyper Go.
- Hyperice X: Last month, Hyperice introduced its latest innovation and the world's first portable contrast therapy device. Hyperice X creates a localized cycle of alternating heat and cold to the knee area for recovery and rehabilitation. Hyperice X will be available globally beginning in 2022.
- Hypervolt 2: The Hypervolt 2 offers noticeable updates from the original, including an improved ergonomic design and reduced weight. Three speeds of powerful percussion help give muscles the relief they’ve been asking for, every day.
- Hypervolt 2 Pro : With the Hypervolt 2 Pro, users will get the same powerful percussion massage therapy that the world’s best athletes have, right in the palm of their hand. Five speeds, set by a new adjustable dial, provide relief to stiff muscles, so users can train and recover like a pro.
- Vyper 3 : All systems activated. The Vyper 3 vibrating roller’s updated design and three speeds help to prime and warm-up the body with a powerful vibrating massage.
- Vyper Go : The next iteration of Hyperice’s “Go” line. Following the release of the Hypervolt Go in 2020, the Vyper Go is a portable, vibrating roller that helps activate muscles, so users can feel their best before activity at home or on the go.
The Vyper 3 is now available in Europe and the United States, and the Hypervolt 2, Hypervolt 2 Pro and Vyper Go are now available in Australia, Canada, China, Europe, New Zealand and the United States with other markets to follow.
Hyperice’s new modern approach and reimagined product innovation allows Hyperice to reimagine how it serves a broader audience of athletes and helps people everywhere do the things they love, and do it more.
For more information, visit hyperice.com. To purchase, please visit country-specific sites: Australia, Canada, China, France, Germany, Italy, New Zealand, Portugal, Spain, UK and the United States.
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies in 2021, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005407/en/
Contact information
Jack Taylor PR
Nadine Hachicho
hyperice@jacktaylorpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 04:00:00 EEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202628.5.2026 00:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, senior author of the NEJM manuscript and first author of the ASCO abstract, said: “Results from the HERIZON-GEA-01 published in The New England Journal of Medicine and presented in an oral presentation at ASCO provide ne
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 18:22:00 EEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 17:00:00 EEST | Press release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 16:00:00 EEST | Press release
ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527813115/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov Growth When ClickHouse closed its $400 million Series D in January 2026, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
